- Home
- ASG vs AGEN Comparison
ASG vs AGEN Comparison
Compare ASG & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASG
- AGEN
- Stock Information
- Founded
- ASG 1986
- AGEN 1994
- Country
- ASG United States
- AGEN United States
- Employees
- ASG N/A
- AGEN N/A
- Industry
- ASG Investment Managers
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ASG Finance
- AGEN Health Care
- Exchange
- ASG Nasdaq
- AGEN Nasdaq
- Market Cap
- ASG 327.2M
- AGEN 97.7M
- IPO Year
- ASG N/A
- AGEN 2000
- Fundamental
- Price
- ASG $5.72
- AGEN $4.50
- Analyst Decision
- ASG
- AGEN Buy
- Analyst Count
- ASG 0
- AGEN 3
- Target Price
- ASG N/A
- AGEN $10.00
- AVG Volume (30 Days)
- ASG 324.3K
- AGEN 346.0K
- Earning Date
- ASG 01-01-0001
- AGEN 11-05-2024
- Dividend Yield
- ASG 8.09%
- AGEN N/A
- EPS Growth
- ASG N/A
- AGEN N/A
- EPS
- ASG N/A
- AGEN N/A
- Revenue
- ASG N/A
- AGEN $159,630,000.00
- Revenue This Year
- ASG N/A
- AGEN N/A
- Revenue Next Year
- ASG N/A
- AGEN $0.04
- P/E Ratio
- ASG N/A
- AGEN N/A
- Revenue Growth
- ASG N/A
- AGEN 60.67
- 52 Week Low
- ASG $4.47
- AGEN $4.18
- 52 Week High
- ASG $5.71
- AGEN $19.69
- Technical
- Relative Strength Index (RSI)
- ASG 64.98
- AGEN 40.31
- Support Level
- ASG $5.66
- AGEN $4.50
- Resistance Level
- ASG $5.65
- AGEN $4.78
- Average True Range (ATR)
- ASG 0.05
- AGEN 0.29
- MACD
- ASG 0.00
- AGEN 0.02
- Stochastic Oscillator
- ASG 85.71
- AGEN 30.77
About ASG Liberty All-Star Growth Fund Inc.
Liberty All Star Growth Fund Inc is the United States based diversified, closed-end management investment company. Its investment objective is to seek long-term capital appreciation through investment in a diversified portfolio of equity securities. The company portfolio of investments consists of different industries such as consumer discretionary, consumer staples, healthcare, industrial, information technology and others.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).